Fluoxetine, a serotonin reuptake inhibitor (SSRI), has other effects in addition to blocking serotonin reuptake, including changes in the vasomotor tone. Whereas many studies focused on the acute effects of fluoxetine in the vasculature, its chronic effects are still limited. In the present study, we tested the hypothesis that chronic fluoxetine treatment modulates adrenergic vascular responses by interfering with post-and pre-synaptic mechanisms. Wistar rats were treated with vehicle (water) or chronic fluoxetine (10 mg/kg/day) for 21 days. Blood pressure (BP) and heart rate were measured. Vascular reactivity was evaluated in perfused mesenteric arterial beds (MAB) and in mesenteric resistance arteries. Protein expression by western blot analysis or immunohistochemistry, β-arrestin recruitment by BRET and calcium influx by FLIPR assay. Fluoxetine treatment decreased phenylephrine (PE)-induced, but not electrical-field stimulation (EFS)-induced vasoconstriction. Fluoxetine-treated rats exhibited increased KCl-induced vasoconstriction, which was abolished by prazosin. Desipramine, an inhibitor of norepinephrine (NA) reuptake, increased EFS-induced vasoconstrictor response in vehicle-treated, but not in fluoxetine-treated rats. Chronic treatment did not alter vascular expression of α 1 adrenoceptor, phosphorylation of PKCα or ERK 1/2 and RhoA. On the other hand, vascular contractions to calcium (Ca 2+ ) as well as Ca 2+ influx in mesenteric arteries were increased, while intracellular Ca 2+ storage was decreased by the chronic treatment with fluoxetine. In vitro, fluoxetine decreased vascular contractions to PE, EFS and Ca
Introduction
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that, in addition to its antidepressant effect, has actions in the cardiovascular system. Fluoxetine interferes with cardiac contractility and heart rate as well as with atrium-ventricular conduction, producing a negative inotropic effect (Park et al., 1999) , QT interval prolongation (Curtis et al., 2003) and arrhythmogenic effects, as tachycardia (Pacher and Kecskemeti, 2004) . Fluoxetine also increases sympathetic activity in the heart and adrenal medulla by increasing tyrosine hydroxylase and dopamine beta-hydroxylase gene expression, which augments noradrenaline synthesis (Spasojevic et al., 2010) and stimulates vasopressin secretion, resulting in increased blood pressure (Lazartigues et al., 2000) .
In elderly patients the chronic use of fluoxetine increases the susceptibility of developing hypertension (Hussein and Kaufman, 1994) and stroke (Hung et al., 2013) .
In addition, fluoxetine treatment during pregnancy increases by approximately 10% the risk of gestational hypertension and preeclampsia (Toh et al., 2009 ) and the risk of the newborn to develop persistent pulmonary hypertension (Kieler et al., 2012) .
Fluoxetine also inhibits the function of several receptors and ion channels, such as 5-HT 2C (Ni and Miledi, 1997) and 5-HT 3 receptors (Fan, 1994) , nicotinic receptors (Maggi et al., 1998) , sodium (Na + ) and potassium (K + ) voltage-dependent channels (Pancrazio et al., 1998; Perchenet et al., 2001; Thomas et al., 2002) and chloride (Cl -) channels (Maertens et al., 1999) , many of them directly involved in the regulation of vasomotor tone.
Although it is clear that fluoxetine produces cardiovascular effects, its actions in the cardiovascular system are not fully understood. In addition, whereas many studies focused on the acute effects of fluoxetine in the vasculature, chronic effects of this SSRI are still limited. Crestani et al. (2011) investigating the effects of chronic administration of fluoxetine in rats, have demonstrated that fluoxetine alters pressor/depressor responses induced by the administration of vasoactive agents, indicating direct vascular effects. We have recently shown that chronic treatment with fluoxetine increases endothelium-dependent and -independent relaxation responses in rat mesenteric resistance arteries by mechanisms involving increased endothelial nitric oxide synthase (eNOS) activity, nitric oxide (NO) generation, and activation of calcium-activated potassium channels (K Ca ) (Pereira et al., 2015) . In addition, Ribback et al. (2012) reported that fluoxetine decreases contractile responses of isolated rat aortic rings to different agonists, including norepinephrine (NA) and serotonin, by NOmediated mechanisms.
Therefore, primarily based on the facts that acute administration of fluoxetine increases sympathetic activity and has direct effects in the vasculature, e.g. decreasing NA-mediated contractile response, we tested the hypothesis that chronic fluoxetine treatment decreases adrenergic vascular responses by interfering with both post-and presynaptic mechanisms. To address our hypothesis, we used two vascular preparations from Wistar rats chronically treated with vehicle or fluoxetine. The vascular preparations were submitted to adrenergic stimuli, α 1 adrenoceptor (α 1 -AR) agonist and electrical-field stimulation (EFS) of sympathetic nerves, as well as to biochemical/molecular protocols to determine mechanisms by which chronic fluoxetine treatment alters vascular reactivity.
Material and methods

Animals
All experimental protocols performed in this study were approved by the Ethics Committee on Animal Experiments of the Ribeirao Preto Medical School, University of Sao Paulo (protocol. 013/2013) and are in accordance with the Guidelines of the National Council for Animal Experimentation Control (CONCEA).
Male Wistar rats, weighing 230-250 g were used in the present study. The animals were housed in high-top-filter cages (3 rats per cage -48.3 cm× 33.7×25.3 cm) in a room with controlled humidity (45 ± 5%) and temperature (21 ± 2°C), and light/dark cycles of 12 hs. Animals had free access to food (commercially available standard rat chow, Purina) and potable tap water.
Treatment with fluoxetine
Fluoxetine was administered (10 mg/kg/day) in the drinking water, which was daily changed (Alper, 1992; Lino-de-Oliveira et al., 2001) . The average consumption of water by the rats was monitored for three days, and the concentration required to achieve a dose of 10 mg/kg/ day was calculated. Treatment of rats with fluoxetine at the same dose (10 mg/kg/day) and same administration route, for 30 days, has been shown to produce clinically-relevant plasma concentrations (Able et al., 2014; McNamara et al., 2010) . The bottles were light-protected to prevent degradation or oxidation of the drug. Rats were divided randomly into two groups: (I) vehicle, water for 21 days or (II) chronic fluoxetine (10 mg/kg/day for 21 days).
Determination of blood pressure and heart rate
Experiments were carried out in conscious, unrestrained rats, in their own cages, 24 h after surgery. The rats (n=20) were subcutaneously anesthetized with a mixture of ketamine (50 mg/kg) and xylazine (10 mg/kg). A polyethylene catheter (PE-10, 0.61 mm outer diameter, inner diameter 0.28 mm, Clay-Adams) was implanted into the left femoral artery for direct measurement of arterial BP. The catheters was filled with heparinized saline (100 IU/ml), capped and tunnelled subcutaneously to the back of the neck. On the day of the experiment, the arterial catheter was connected to a pressure transducer (model DPT-100 Deltran; Utah Medical Products, Midvale, Utah) and the rats allowed to rest for 15-20 min. After the rest period, arterial pressure was continuously sampled (4 kHz) during 30 min, using a computer equipped with an analogic-to-digital interface (PowerLab/4SP; ADInstruments, Colorado Springs, CO).
Vascular reactivity -mesenteric arterial bed
Isolated and perfused MAB rat, which allows measurements of mesenteric vascular reactivity, were used as previously described by Macgregor, 1965 . Briefly, rats were anaesthetized with a mixture of ketamine (50 mg/kg) and xylazine (10 mg/kg), given intraperitoneally; the abdominal cavity was opened and the intestinal loops were exposed. The superior mesenteric artery was dissected close to its origin in the abdominal aorta and cannulated with a PE-50 polyethylene catheter. The MAB was perfused with 1 ml Krebs Henseleit solution (KHS) [(in mmol/L): NaCl 120; KCl 4.7; KH 2 PO 4 1.17; MgCl 2 1.43; NaHCO 3 25; Glucose 11; EDTA 0.03; CaCl 2 3.0] containing heparin (500 IU). The intestinal loops were removed en bloc, the MAB was separated by cutting close to the intestinal loops, and the preparation was placed in a cuvette warmed to 37°C. The cannulated superior mesenteric artery was coupled to a perfusion pump and the MAB was perfused with Krebs solution bubbled with 95% O 2 and 5% CO 2 , pH 7.4, at a constant flow of 4 ml/min. A pressure transducer (Deltran® Disposable Pressure Transducer, 6069, Utah Medical) was coupled in a 'y' arrangement to the system for perfusion pressure recording. The pre-amplified and filtered outlet signal was coupled to the data acquisition system (AECAD 04F) connected to a computer, and stored for later analysis using the AQCAD software.
After a 30-min stabilization period, preparation steps were undertaken to perform dose-response curves. Mesenteric arterial beds were stimulated with increasing doses of phenylephrine [(PE) 300 pmol, 1, 3, 10, 30, 100, 300 nmol, 1, 3 and 10 μmol, administered in bolus] to produce contractions that were measured as increases in basal perfusion pressure. MABs were also stimulated with increasing concentrations of KCl (30, 45 and 60 mM) to produce contractions in the absence and presence of prazosin, an α 1 adrenoceptor antagonist (10 nM).
In a separate set of experiments, MAB were submitted to EFS. A bipolar electrode steel wire was placed around the superior mesenteric artery, stimulating the vessel wall and periarterial nerves. This electrode was connected to a current stimulator (AVS Avs-100C4-USB), releasing rectangular pulses of 5 ms duration, 34 V amplitude, and each stimulus train lasted 20 s (Salgado et al., 1992) . The frequencies of stimuli ranged from 7 to 30 Hz to obtain the frequency-response curve vasoconstrictor (7, 10, 12, 15, 20, 25 and 30 Hz) in absence or presence of desipramine, an inhibitor of NA reuptake (10 nM) (Salgado et al., 1992) . The interval for each train of stimuli was 3 min.
Vascular reactivity -isolated mesenteric resistance arteries
The method described by Mulvany and Halpern (1977) (0.5, 1, 1.6, 2 and 2.5 mM) to produce a contraction (measured as increases in baseline tension).
In another set of experiments, Ca 2+ release from intracellular stores was evaluated using the protocol described by Karaki et al. (1979) and Perry and Webb (1991 -KHS, and after 2 min, the arteries were stimulated with caffeine (20 mM), in order to deplete intracellular Ca 2+ stores, which resulted in a transient contraction (Karaki et al., 1979; Perry and Webb, 1991) . Contractile responses to EFS were also determined in mesenteric resistance arteries. EFS was applied to arteries placed between platinum pin electrodes. EFS was conducted at 20 V, 1-ms pulse width, and trains of stimuli lasting 10 s at varying frequencies (1-32 Hz).
Immunohistochemistry for tyrosine hydroxylase
Subbed slides containing coronal sections of mesenteric arteries (10 µm) were initially submitted to blockade of endogenous peroxidase with 0.03% H 2 O 2 (hydrogen peroxide), followed by the blockade of non-specific binding sites with 5% bovine serum albumin (BSA). Subsequently, for visualization of tyrosine hydroxylase immunoreactivity, slides were incubated for 12-14 h in a humid chamber at room temperature with the primary antibody (anti-tyrosine hydroxylase, Millipore, #MAB318, 1:1000 in 0.1 M phosphate buffer containing 2% normal goat serum and 0.3% Triton X-100) and then incubated with the biotinylated secondary antibody (Goat anti-Mouse (Vector, #BA9200), 1:200 in 0.1 M phosphate buffer containing 1.5% normal goat serum and 0.3% Triton X-100) for a period of 2 h. The avidinbiotin-peroxidase method was used (PK-6100, Vector, 1:200) and the reaction with diaminobenzidine (DAB, D-5637, Sigma) produced a brown color, which was representative of positive immunoreactivity for tyrosine hydroxylase. After these procedures, sections were dried at room temperature and then dehydrated with xylene and covered with mounting media. Representative sections of 4-5 animals from each experimental condition were captured in high resolution by a camera attached to a microscope (Leica) and transmitted to a software (Leica Application Suite, version 3.7).
Western blot
The MAB was isolated in ice-cold Krebs solution, cleaned from adventitial tissue and immediately frozen in liquid nitrogen. The tissue was pulverized and homogenized in ice-cold lysis buffer [Triton X-100 1%, 100 mM Tris (pH 7.4), 100 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM ethylene diamine tetraacetic acid (EDTA), 10 mM sodium orthovanadate, 2 mM phenyl methyl sulfonyl fluoride (PMSF) and aprotinin 0.01 mg/ml]. Tissue extracts were centrifuged, and total protein content was quantified using the Bradford method (Bio-Rad) (Bradford, 1976) .
Proteins (40-100 μg) were then separated by electrophoresis in polyacrylamide (SDS-PAGE) gel and transferred to nitrocellulose membranes. Nonspecific binding sites in the membrane were blocked with 1% BSA in Tris-buffered saline solution with 1% of Tween (TBS-T) for 1 h at room temperature. Membranes were then incubated at 4°C with specific antibodies, overnight. Membranes were washed 3 times with TBS-T and incubated with specific secondary antibodies for 1 h at room temperature. Signals were revealed after reaction with ECL (Amersham ECL Prime Western Blotting Detection Reagent) and the images captured in ImageQuant 350 (GE Healthcare, Piscata Way, NJ, USA).
Results were normalized by the total protein or membrane/ cytosolic fraction ratio in the experimental protocols. Antibodies dilutions were used as follows: Anti-PKC alpha-antibody (1:250, Abcam, Ab4124); Anti-phospho-PKC alpha-antibody (S657/Y658) (1:1000, Abcam, Ab23513); Anti-phospho-Erk1/2 (Thr202/Tyr204, Thr185/Tyr187) (1:1000, Millipore, 05-797 R); Anti-Erk1/2 (p44/ p42) Antibody (1:1000, Millipore, 05-1152), β-arrestin 1/2 (D24H9) (1:500, Cell Signaling, #4674), Anti-α 1 adrenoceptor antibody (1:400, Abcam, ab3462) and β-actin #2148 S (1:3000, Cell Signaling).
BRET assay
For BRET assays, we used HEK293T cells that were maintained in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin/streptomycin, at 37°C in 5% CO 2 . HEK293T cells in 10-cm dishes were transiently transfected using polyethylenimine (PEI; 25 kDa linear; Polysciences, Warrington, PA, USA) at a ratio of 3:1 PEI/DNA. In each plate we cotransfected 2.5 μg of α 1 b-AR fused to GFP and 125 ng of βarr1-RlucII or βarr2-RlucII and salmon sperm DNA (Invitrogen, Carlsbad, CA, USA) was used to adjust to 10 μg the total amount of DNA transfected. Cells were maintained in culture and 48 h after the transfection the BRET experiments were performed as described previously (Quoyer et al., 2013; Santos et al., 2015) . Briefly, cells were washed once with PBS and after detached were seeded in 96-well white plates (OptiPlate; PerkinElmer). BRET signals were measured using the Victor™ X Light Luminescence microplate reader (PerkinElmer) and determined as the ratio of the light emitted by acceptors (GFP) over donors (RlucII). Coelenterazine h 5 µM (Biotium, Hayward, CA, USA) was used as the luciferase substrate and BRET values were collected using the energy acceptor filter (535 ± 15 nm) and the energy donor filter (460 ± 40 nm). Full concentration-response curves were performed in cells stimulated with fluoxetine, norepinephrine or both for 10 min.
Cell culture
Male Wistar rats were euthanized and vascular smooth muscle cells (VSMCs) from the MAB were isolated and characterized as previously described (Chignalia et al., 2012) . Briefly, arteries were cleaned of adipose and connective tissue and VSMCs were dissociated by digestion of arteriolar arcades with an enzymatic solution, consisting of (in mg/ml) 2 collagenase, 0.12 elastase, 0.36 soybean trypsin inhibitor, and 2 bovine serum albumin (BSA) type I in Ham's F-12 culture medium.
Cells were incubated for 45 min at 37°C and then filtered through a 100-μm nylon mesh. The cell suspension was centrifuged at 2,000g and resuspended in DMEM (Gibco, Carlsbad, CA), supplemented with 10% bovine serum, 2×10
−3 mol/l glutamine, 2×10 −2 mol/l HEPES (pH 7.4), and antibiotics. VSMCs were identified by determination of α-actin expression by fluorescence microscopy, and the absence of endothelial cells was confirmed by assessment of von Willebrand factor by realtime polymerase chain reaction (PCR; data not shown). Subconfluent cell cultures were rendered quiescent by serum deprivation for 24 h before experimentation. Low-passage cells (passages 4-7) from at least four different primary cultures were used in our experiments.
Intracellular calcium mobilization
In the Ca 2+ mobilization assay, VSMC were seeded in black-walled, clear-bottomed 96-well plates (Corning, NY) at a density of 50,000 cells/well in DMEM with 10% fetal bovine serum and incubated for 24 h at 37°C in a 5% CO 2 incubator. The following day, the culture media was incubated with fluoxetine or vehicle for 1 or 24 h and after replaced with 100 μL of Hank's Balanced Salt Solution with 20 mM HEPES, and the cells were loaded with 100 μL of dye solution (Molecular Devices, Sunnyvale, CA) for 1 h at room temperature before addition of compounds. Transient changes in Ca 2+ concentration induced by adenosine triphosphate (ATP) (10 −10 to 10 −5 M) were measured using the FlexStation® instrument using SoftMax® Pro software (Molecular Devices, Sunnyvale, CA). Changes in fluorescence were detected at the emission wavelength of 515-575 nm. ATPinduced responses were determined immediately upon its addition and measured as peak fluorescent intensity minus basal fluorescent intensity and calculated the area under the curve.
Drugs
Fluoxetine, phenylephrine, acetylcholine, desipramine, ATP, norepinephrine and caffeine were from Sigma-Aldrich (St. Louis, MO, U.S.A.) and prazosin was from Tocris (Ellisville, MO, U.S.A).
Data Analysis
Results are expressed as mean ± standard error of the mean (S.E.M.). Contractile responses in MAB are represented as the change of perfusion pressure (mmHg) from the basal perfusion pressure. Contraction responses in mesenteric arteries are expressed as the percentage of contraction to KCl. Concentration-response curves were analysed by non-linear regression using the software GraphPad Prism (GraphPad Prism 5.0, GraphPad Software Inc., San Diego, CA, USA). The potency of agonists is expressed as pD 2 (negative logarithm of the molar concentration that produces 50% of the maximal response), E max (Maximum possible effect for the agonist) and the potency of frequency is expressed as F 50 (frequency that produces 50% of the maximal response). Statistical analysis of the pD 2, E max and F 50 values was performed using non-linear regression analysis followed by Student "t" test or one-way analysis of variance (ANOVA).
The unpaired "t" test was used in western blot analyses. Student's ttest was used in western blot analyses and quantification of TH staining, which was performed in one section per experimental animal using Image J® software, set with the same color threshold to all analysed groups. Results were expressed as area of TH-positive particles (μm 2 ). The differences were considered significant when was P < 0.05.
Results
3.1. Effects of chronic treatment with fluoxetine on arterial pressure and heart rate Fluoxetine treatment did not change systolic, diastolic and mean arterial pressure or heart rate, in baseline conditions (Fig. 1). 
Effects of chronic treatment with fluoxetine on contractile adrenergic responses
Responses to phenylephrine and to EFS in the presence of vehicle or an inhibitor of NA reuptake, as well as KCl-induced contractions in the presence of an α 1 adrenoceptor antagonist or vehicle were performed to determine changes in pre-and post-synaptic mechanisms Fig. 1 . Effects of chronic treatment with fluoxetine on blood pressure and heart rate. Mean (A), systolic (B), and diastolic (C) blood pressure and heart rate (D) of Wistar rats chronically treated with vehicle (Veh) or fluoxetine (Fluox). Each column represents the mean ± S.E.M. N=9-11.
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European Journal of Pharmacology 800 (2017) 70-80 contributing to the abnormal vascular response in fluoxetine-treated animals. Fluoxetine decreased PE-induced contractions in MAB [(pD 2 ) Fluox=6.9 ± 0.12 vs. Veh =7.8 ± 0.11; Fig. 2A and (E max ) Fluox=60.3 ± 3.5 vs. Veh=83.4 ± 3.3; Fig. 2B ; N=5-6, P < 0.05]. Vascular contractile responses induced by EFS were similar between the groups [(F 50 ) Fluox=14.9 ± 0.3 vs. Veh=14.9 ± 0.6; Fig. 2C ]. On the other hand, contractions to KCl were increased in MAB from rats chronically treated with fluoxetine [(ΔmmHg) at 45 mM KCl, Fluox=25.5 ± 2.7 vs. Veh=17.2 ± 1.0; at 60 mM KCl, Fluox =38.9 ± 2.7 vs. Veh=30.3 ± 2.3; N=6-7, P < 0.05; Fig. 2D ].
Role of α 1 adrenoceptor in the increased vasoconstrictor responses to KCl, and Norepinephrine transporter (NET) in vasoconstrictor response to EFS
Increased KCl-induced vasoconstriction in fluoxetine-treated rats was abolished in the presence of prazosin [(ΔmmHg), at 45 mM KCl, Fluox=19.4 ± 3.4 vs. Veh=17.5 ± 1.1; at 60 mM KCl, Fluox=27.5 ± 4.0 vs. Veh=26.4 ± 1.2, N=4-5; Fig. 3A) .
To determine changes in the expression of tyrosine hydroxylase, the rate limiting step enzyme in NA synthesis, immunohistochemistry was performed. Chronic treatment with fluoxetine significantly decreased TH expression in mesenteric arteries when compared with the vehicle group [(Area Under the Curve [AUC]) Fluox=3921 ± 981.8 vs. Veh=7269 ± 499.7, N=3-5, P < 0.05; Fig. 3B ]. To determine functional changes in NA reuptake, EFS-induced contractions were determined in the presence of a NA reuptake inhibitor. Desipramine increased EFSinduced contractions in the vehicle-treated group, but not in the fluoxetine-treated group [(E max ) Fluox=42.1.6 ± 2.5 vs. 44.4 ± 3.7; Veh=34.6 ± 3.6 vs. 53.3 ± 2.8; N=5, P < 0.05; Fig. 3C ).
3.4. Effects of chronic treatment with fluoxetine on α 1 -AR expression and proteins involved in signaling pathways activated by α 1 adrenoceptor (PKCα, protein kinase C alpha, RhoA, membrane/cytosol ratio of Ras homolog gene family, member A and ERK1/2, extracellular-regulated kinase 1/2) Western blot analysis was performed to determine alterations in the expression/activity of signaling proteins involved in α 1 adrenoceptor activation-induced vasoconstriction.
Expression of α 1 -AR in the MAB was similar between the vehicleand fluoxetine-treated groups [(arbitrary units [.U.]) Fluox=0.7 ± 0.1 vs. Veh=0.7 ± 0.1; N =4, Fig. 4A ]. There were no differences in the expression of phosphorylated forms of PKCα and ERK1/2 or in the membrane and cytosolic fractions ratio of RhoA between the vehicleand fluoxetine-treated groups [(A.U.) PKCα, Fluox=0.7 ± 0.1 vs. Veh=0.8 ± 0.1; ERK1/2, Fluox=0.5 ± 0.1 vs. Veh=0.6 ± 0.1; RhoA, Fluox=0.2 ± 0.1 vs. Veh=0.2 ± 0.1; N=3-5, Fig. 4B , C and D, respectively].
Effects of fluoxetine on β-arrestin activity
BRET analysis was performed to determine whether fluoxetine directly modulates beta-arrestin activity or whether changes in betaarrestin activity are due to fluoxetine indirect effects.
Chronic treatment with fluoxetine significantly increased β-arrestin activity, evidenced by increased translocation of β-arrestin to the cell membrane and evaluated by the expression ratio of β-arrestin in membrane and cytosolic fractions of MAB [(A.U.), Fluox=0.53 ± 0.1 vs. Veh=0.22 ± 0.1; N=4, P < 0.05, Fig. 5A ]. To investigate whether fluoxetine directly induces β-arrestin recruitment to α 1b -AR or affects recruitment of β-arrestin triggered by NA, we used the BRET-based biosensors (Charest et al., 2005) . Ligand-promoted changes in BRET 
C.A. Pereira et al.
European Journal of Pharmacology 800 (2017) 70-80 were monitored in cells co-expressing the α 1b-AR and either βarrestin1-RlucII or βarrestin2-RlucII. Cells were stimulated with fluoxetine, NA (10 -11 M to 10 −5 M), or both. As shown in Fig. 5B , fluoxetine did not induce β-arrestin 1 or 2 recruitment, neither promoted significant changes in NA-induced β-arrestin recruitment. -induced contractions in the presence of KCl, were slightly, but significantly increased in mesenteric arteries from fluoxetine-treated rats [(E max ) Fluox=88.1 ± 1.7 vs. Veh=79.2 ± 2.3; N=5-6, P < 0.05, Fig. 6A ).
To evaluate Ca 2+ release from intracellular stores, mesenteric arteries from vehicle-and fluoxetine-treated rats were stimulated with a single concentration of PE (10 μM), which exhibited similar contractile responses under this condition [(mN) Fluox=80.7 ± 5.6 vs. Veh=77.9 ± 6.0; N=6, Fig. 6B ]. After depletion of intracellular Ca 2+ stores, Ca 2+ influx was indirectly determined by the contractions displayed during the loading period, as previously described. Contractile responses evoked during the loading period were increased in mesenteric arteries from fluoxetine-treated rats [(mN) Fluox=14.2 ± 3.9 vs. Veh=3.9 ± 1.9 vs.; N=6, P < 0.05, Fig. 6C ]. The amount of Ca Mesenteric arteries from fluoxetine-treated rats displayed decreased caffeine-induced contractions compared to arteries from vehicle-treated rats [(mN) Fluox=16.8 ± 4.6 vs. 33.3 ± 3.8; N=6, P < 0.05, Fig. 6D ],
indicating that chronic treatment with fluoxetine decreases intracellular Ca 2+ storage.
Acute vascular effects of fluoxetine
PE-induced contractions [(pD 2 ) Fluox=6.0 ± 0.03 vs. Veh=6.2 ± 0.04 and (E max ) Fluox=106.6 ± 2.8 vs. Veh =125.3 ± 3.3; N=5, P < 0.05, Fig. 7A ] as well as EFS-induced contractile responses [(E max ) Fluox=34.2 ± 5.1 vs. Veh =89.6 ± 6.9; N=5, P < 0.05, Fig. 7B ) were decreased in mesenteric arteries incubated for 1 h with fluoxetine. Ca 2+ -induced contractions in the presence of KCl were also decreased in arteries from control rats incubated for 1 h with fluoxetine [(E max ) Fluox=58.2.3 ± 6.1 vs. Veh=76.8 ± 2.5; N=5, P < 0.05, Fig. 7C ].
FLIPR technique was used to evaluate whether fluoxetine influences intracellular calcium levels. Fluoxetine inhibited, in a timedependent manner, the increases in cytosolic Ca 2+ induced by the purinergic agonist ATP in isolated VSMC [(AUC) 1 h incubation, Fluox=21190 ± 571 vs. Veh=24945 ± 235; 24 h incubation, Fluox=4255 ± 36 vs. Veh=24547 ± 533; N=5, P < 0.05, Fig. 7D ].
Discussion
Adverse effects of fluoxetine, particularly those on the central nervous system, are well described. However, fluoxetine effects on the cardiovascular system, especially after its chronic use, are still scarce. Fluoxetine has properties beyond its antidepressant effects, altering mechanisms involved in the regulation of BP and vasomotor tone. Due to the high consumption of fluoxetine is of utmost importance to better know the actions of this drug.
Crestani et al. (2011) showed that rats treated for 21 days with fluoxetine display a slight increase of BP and decreased pressor and . Each point in the frequency-response curves or each column represents the mean ± S.E.M. The quantification of TH staining was performed using Image J® software and data were analysed by Student's t-test. Scale bar: 100 µm. N=5 (Veh) -7 (Fluox) for frequency-response experiments and N=3 (Veh) −5 (Fluox) for TH immunoreactivity. *, P < 0.05 vs. Veh; #, P < 0.05 vs. Fluox.
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European Journal of Pharmacology 800 (2017) 70-80 depressor responses to vasoactive agents, suggesting that fluoxetine may alter the mechanisms that regulate the vasomotor tone. However, studies performed on human and animal models have reported very controversial results. Roose et al. (1998) , Thase et al. (2005) and Jain et al. (1992) demonstrated that fluoxetine treatment did not change BP in depressive or mood disorders patients. Conversely, Chugh et al. (2013) showed that mice fluoxetine-treated had increased BP values. Hussein and Kaufman (1994) also reported increased BP in elderly depressive patients after 18 months of treatment. Finally, Amsterdam et al. (1999) observed a modest reduction in BP in depressive patients treated for 12 weeks. In the present study chronic treatment with fluoxetine did not change BP, corroborating results from some of the above-mentioned reports.
Structural and functional vascular changes contribute to abnormal vasoconstrictor and vasodilator responses and, consequently, to changes in BP (Chai and Webb, 1988) . There are different available methods to study functional changes in the vasculature. In the present study, we performed protocols using two vascular preparations: the isolated and perfused MAB and isolated second-order mesenteric resistance arteries.
The MAB is responsible for accommodating approximately 20-40% of total blood volume (Aires, 2008) , and represents an important vascular resistance bed, involved in blood flow and BP regulation (Furness and Marshall, 1974) .
In our first experiments, we observed that MAB from animals fluoxetine treated exhibited reduced contractions to PE, an α 1 -AR agonist. These results are consistent with those described by Ribback et al. (2012) , demonstrating that different antidepressants reduce contractile response to adrenergic agonists.
Our results also indicate that TH expression was significantly lower in slices of mesenteric arteries after chronic treatment with fluoxetine, an effect that was also observed by other groups in different brain regions (Oliva et al., 2005; Ordway and Szebeni, 2004; Rovin et al., 2012) .
Previous results from our group demonstrated that chronic treatment with fluoxetine increases NO availability promoting greater activation of K Ca channels and facilitating vasodilation, which may also contribute to the reduced vasoconstrictor responses (Pereira et al., 2015) .
Although PE-induced contractions were decreased in MAB, KClinduced contractile responses were increased, indicating that fluoxetine changes specific signaling pathways. In addition, KCl-induced depolarization affects the whole preparation, including nerve terminals. In order to test whether increased KCl-induced vasoconstriction was due to increased release of adrenergic neurotransmitters, the same protocol was performed in the presence of prazosin, a α 1 -AR antagonist. In this experimental condition, contractions induced by KCl were similar in MAB from vehicle-and fluoxetine-treated rats, indicating an increased release of NA in MAB from fluoxetine-treated animals.
Regarding the central effects of fluoxetine on cardiovascular function, Lazartigues et al. (2000) demonstrated that fluoxetine intracerebroventricular administration increases sympathetic tone and vasopressin release.
Other studies demonstrated that fluoxetine reduces the expression of the serotonin transporter, 5HTT, among other genes, and this effect seems to be associated with the therapeutic benefits of this drug on neuropsychiatric disorders (Oliva et al., 2005 ; Ordway and Szebeni, Our results demonstrate a trend to a lower reuptake of NA in fluoxetine-treated animals since desipramine, NA reuptake inhibitor, did not produced a displacement of EFS-induced contractile responses in MAB of the fluoxetine group. Considering that fluoxetine inhibits NET function and decreases NA reuptake, this would increase the vascular contractile effects of this amine.
Acting as effector hormones or neurotransmitters, epinephrine and NA mediate their actions through of subtypes α 1 , α 2 , β 1 , β 2 and β 3 adrenoceptors. Activation of the α 1 -AR promotes various physiological actions, including smooth muscle contraction and increase of BP (Tanoue et al., 2002) .
Prolonged stimulation of receptors can cause desensitization and decreased responses to the agonist (Garcia-Sainz et al., 2011) . Different cellular processes seem to contribute to receptor desensitization, including modulation of function and expression, internalization, recycling and degradation (Lefkowitz, 1998) . Ramakrishna et al., 2010 observed that fluoxetine treatment resulted in down-regulation of cortical and cerebellar α 1 -AR in rats. Vila et al., 1990 also observed that chronic treatment with different antidepressants reduces the responsiveness to PE, suggesting a desensitization of postsynaptic α 1 -ARs. However, in the present study, fluoxetine did not decrease α 1 -AR MAB expression.
We also tested the hypothesis that the reduction of vasoconstrictor responses to PE are due to decreased expression/phosphorylation of proteins involved in the contraction process. ERK1/2 is an important kinase involved in the regulation of cell proliferation, differentiation, survival and contraction. PKC is a serine/threonine kinase and a member of the conventional (classical) PKCs, which are activated in response to many different kinds of stimuli and are involved in vascular contraction (Nakashima, 2002) . PKCα is the main PKC isoform activated by PE. Rho-kinase activation in response to agonists of Gprotein-coupled receptors induces contraction by increasing Ca 2+ sensitivity of contractile proteins (Hirata et al., 1992) . However, chronic treatment with fluoxetine did not change vascular PKCα, ERK1/2 or RhoA activity.
β-arrestin, in turn, constitutes an important protein involved in termination of plasma membrane receptor signaling (Ligeti et al., 2012) . β-arrestin interact with G proteins stimulating the internalization and consequent degradation or recycling of the receptor (Bohm et al., 1977; Gaborik and Hunyady, 2004) . Our data show increased β-arrestin 1/2 activity, represented by increased expression in the membrane vs. cytosolic fraction in MAB of fluoxetine treated rats. Considering that the BRET-based assay showed that fluoxetine did not trigger recruitment of β-arrestin to α 1b-AR or affected β-arrestin recruitment promoted by NA, our results suggest that increased β-arrestin 1/2 activity is not a direct effect of fluoxetine but may be due to effects of fluoxetine chronic treatment on other systems.
Corroborating our results, Du et al. (2014) demonstrated that fluoxetine increases β-arrestin 2 expression in microglial cells, being this effect associated with an anti-inflammatory effect. Mendez-David et al. (2013) also demonstrated that fluoxetine restores β-arrestin 1 protein levels in depressive patients. The decrease of β-arrestin 1 levels has been described as a predictive marker of the pathophysiology of depression and the antidepressant response.
Another extremely important mechanism that controls VSMC tone is intracellular Ca 2+ levels. This ion has a key role in the regulation of numerous biological processes such as contraction, cell division and Gobin et al. (2015) also demostrated that fluoxetine suppresses Ca 2+ signaling in human T lymphocytes through depletion of intracellular Ca 2+ stores. Vasorelaxant properties of fluoxetine have also been demonstrated in skeletal muscle arteries and cerebral arteries , and are related to inhibition of Ca 2+ channels, which affect signaling transduction elicited by 5-HT and NA. In summary, chronic treatment with fluoxetine modulates vascular sympathetic adrenergic responses by modifying pre-synaptic mechanisms -it inhibits NA reuptake, increases noradrenaline availability in the synaptic cleft and down-regulates TH -as well as post-synaptic mechanisms -it increases beta-arrestin activity and decreseas calcium stores in vascular smooth muscle cells, promoting decreased vasoconstrictor responses. Reduced vasoconstriction may contribute to decreased peripheral vascular resistance and decreased blood pressure leading to orthostatic hypotension, a side effect associated with chronic treatment with fluoxetine. These data may contribute to a better understanding of the cardiovascular actions produced by chronic treatment with fluoxetine.
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